This paper covers:
- the SNF decision
- evidentiary challenges
- attempts to stem the tide of losses
- evidence of a global market
- OECD guidelines
- Roche Australia v the Commissioner of Taxation
- relevant facts
- expert reports
- appropriate choice of comparables
- contract between RB and Bayer AG ("Inhibace")
- choice of OECD methodology.